Literature DB >> 23459034

Prostate cancer: targeting prostate tumour angiogenesis with cediranib.

Sarah Payton.   

Abstract

Entities:  

Year:  2013        PMID： 23459034     DOI： 10.1038/nrurol.2013.46

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.

Authors:  William L Dahut; Ravi A Madan; Joyson J Karakunnel; David Adelberg; James L Gulley; Ismail B Turkbey; Cindy H Chau; Shawn D Spencer; Marcia Mulquin; John Wright; Howard L Parnes; Seth M Steinberg; Peter L Choyke; William D Figg
Journal:  BJU Int       Date:  2013-02-18       Impact factor: 5.588
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.